Centrus Energy (LEU) 10-Q29 Oct 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Oct. 25, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	1-14287
Entity Registrant Name	Centrus Energy Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-2107911
Entity Address, Address Line One	6901 Rockledge Drive,
Entity Address, Address Line Two	Suite 800,
Entity Address, City or Town	Bethesda
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20817
City Area Code	301
Local Phone Number	564-3200
Title of 12(b) Security	Class A Common Stock, par value $0.10 per share
Trading Symbol	LEU
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001065059
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		15,677,224
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		719,200

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 194.3	$ 201.2
Accounts receivable, net	19.1	49.4
Inventories	190.7	306.4
Deferred costs associated with deferred revenue	74.9	117.6
Other current assets	37.9	10.8
Total current assets	516.9	685.4
Property, Plant and Equipment, Net	8.9	7
Deposits for financial assurance	2.6	32.4
Intangible assets, net	32.2	39.4
Deferred Tax Assets, Net	23	28.5
Other long-term assets	7.4	3.5
Total Assets	591	796.2
Current Liabilities
Accounts payable and accrued liabilities	32.8	41.9
Accounts payable under purchase agreements	0	41.9
Inventories owed to customers and suppliers	0.8	84.3
Contract with Customer, Liability, Current	222.6	282.6
Convertible senior notes (Predecessor)	54.6	14.3
Current debt	6.1	6.1
Total current liabilities	316.9	471.1
Long-term debt	83.5	89.6
Postretirement health and life benefit obligations	75.7	81.2
Pension benefit liabilities	4.6	17.3
Advances from customer, noncurrent	0	32.8
Long-term SWU Loan	26.5	63.1
Other long-term liabilities	7.4	8.8
Liabilities	514.6	763.9
Commitments and contingencies (Note 11)
Stockholders' Deficit
Preferred stock	0	0
Excess of capital over par value	205.2	180.5
Accumulated deficit	(130)	(149.5)
Accumulated other comprehensive income (loss), net of tax	(0.5)	(0.3)
Stockholders' Equity	76.4	32.3
Total Liabilities and Stockholders’ Equity (Deficit)	$ 591	$ 796.2
Common Class A [Member]
Stockholders' Deficit
Common Stock, Shares, Issued	15,677,224	14,956,434
Common stock	$ 1.6	$ 1.5
Common Class B [Member]
Stockholders' Deficit
Common Stock, Shares, Issued	719,200	719,200
Common stock	$ 0.1	$ 0.1

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Preferred Stock, Par Value Per Share	$ 1
Preferred Stock, Shares Authorized	20,000,000
Accumulated Depreciation, Property, Plant, and Equipment	$ 4.9	$ 4.3
Common Class A [Member]
Common Stock, Par or Stated Value Per Share	$ 0.10
Common Stock, Shares, Outstanding	15,677,224	14,956,434
Common Stock, Shares Authorized	70,000,000
Common Stock, Shares, Issued	15,677,224	14,956,434
Common Class B [Member]
Common Stock, Par or Stated Value Per Share	$ 0.10
Common Stock, Shares, Outstanding	719,200	719,200
Common Stock, Shares Authorized	30,000,000
Common Stock, Shares, Issued	719,200	719,200

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from Contract with Customer, Excluding Assessed Tax	$ 57.7	$ 51.3	$ 290.4	$ 216.6
Cost of sales	48.8	40	240.7	154.3
Gross profit (loss)	8.9	11.3	49.7	62.3
Advanced technology license and decommissioning costs	4.1	3.3	13.9	10.8
Selling, general and administrative	10	9.5	25.7	27.5
Amortization of intangible assets	2.4	1.4	7.2	4.2
Operating income (loss)	(7.6)	(2.9)	2.9	19.8
Nonoperating components of net periodic benefit expense (income)	0.8	(0.6)	(15.4)	0.1
Interest expense	0.1	0.4	0.8	0.9
Investment income	(2.6)	(2.3)	(7.8)	(6.4)
Other Nonoperating Income	0	(1)	0.1	(1)
Income (loss) before income taxes	(5.9)	0.6	25.2	26.2
Provision (benefit) for income taxes	(0.9)	(7.6)	5.7	(1.9)
Net income (loss)	$ (5)	$ 8.2	$ 19.5	$ 28.1
Net income (loss) per common share - basic	$ (0.30)	$ 0.53	$ 1.21	$ 1.86
Net income (loss) per common share - diluted	$ (0.30)	$ 0.52	$ 1.20	$ 1.82
Weighted-average number of shares outstanding:
Average number of shares outstanding, basic	16,422	15,374	16,172	15,127
Average number of shares outstanding, diluted	16,422	15,626	16,236	15,415
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 34.8	$ 40.5	$ 228	$ 186.9
Cost of sales	29.6	30.4	189.3	126.1
Uranium [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	29.9	39.5
Separative Work Units [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	34.8	40.5	198.1	147.4
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	22.9	10.8	62.4	29.7
Cost of sales	$ 19.2	$ 9.6	$ 51.4	$ 28.2

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities
Net income (loss)	$ 19.5	$ 28.1
Adjustments to reconcile net income (loss) to net cash (used in) operating activities:
Depreciation and amortization	7.9	4.8
Provision for Loss on Contracts Utilized	0	(16.7)
Deferred tax assets	5.5	(2.3)
Defined Benefit Plan, Actuarial (Gain) Loss From Remeasurement	16.8	0.9
Equity related compensation	1.1	2
Revaluation of inventory borrowing	3.7	3.5
Other Operating Activities, Cash Flow Statement	0	(1)
Changes in operating assets and liabilities:
Accounts receivable – (increase) decrease	30.3	28.7
Inventories – (increase) decrease	85.4	23
Increase Decrease in Inventories Owed to Suppliers	(83.5)	(60.4)
Increase (Decrease) in Prepaid Expenses, Other	3	13.4
Accounts payable and other liabilities – increase (decrease)	(8.8)	(2.5)
Payables under SWU purchase agreements – increase (decrease)	(41.9)	(29.8)
Deferred revenue, net of deferred costs – increase (decrease)	(19.9)	3.7
Pension and postretirement liabilities - increase (decrease)	(6.2)	(1.7)
Other, net	(0.2)	(0.7)
Net Cash (Used in) Operating Activities	(20.9)	(8.8)
Cash Flows Provided by Investing Activities
Capital expenditures	(3.4)	(1.1)
Net Cash Provided by (Used in) Investing Activities	(3.4)	(1.1)
Cash Flows Used in Financing Activities
Proceeds from the sale of common stock, net	23.4	23.2
Payment of interest classified as debt	(6.1)	(6.1)
Payment, Tax Withholding, Share-based Payment Arrangement	(0.3)	(3)
Proceeds from (Payments for) Other Financing Activities	0	(0.2)
Exercise of stock options	0.4	0
Net Cash (Used in) Financing Activities	17.4	13.9
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	0	(0.6)
Decrease in cash, cash equivalents and restricted cash	(6.9)	3.4
Cash, cash equivalents and restricted cash, start of period	233.8	212.4
Cash, cash equivalents and restricted cash, end of period	226.9	215.8
Income Taxes Paid, Net	0.6	0
Property, plant and equipment included in accounts payable and accrued liabilities [Member]
Supplemental Cash Flow Information:
Other Significant Noncash Transaction, Value of Consideration Given	(0.1)	(0.3)
Adjustment to Right of Use Lease due to Modification [Domain]
Supplemental Cash Flow Information:
Other Significant Noncash Transaction, Value of Consideration Given	0	(4.2)
Shares withheld for employee taxes [Member]
Supplemental Cash Flow Information:
Other Significant Noncash Transaction, Value of Consideration Given	$ (0.1)	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Millions	Total	Preferred Stock [Member]	Common Stock [Member] Common Class A [Member]	Common Stock [Member] Common Class B [Member]	Excess of Capital over Par Value [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2022	$ (74.1)	$ 0	$ 1.4	$ 0.1	$ 158.1	$ (233.9)	$ 0.2
Net income (loss)	7.2	0	0	0	0	7.2	0
Stock issued during period	23.2	0	0.1	0	23.1	0	0
Shares withheld for employee taxes	(1.9)	0	0	0	(1.9)	0	0
Other comprehensive income, net of tax	(0.1)	0	0	0	0	0	(0.1)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	1.2	0	0	0	1.2	0	0
Ending Balance at Mar. 31, 2023	(44.5)	0	1.5	0.1	180.5	(226.7)	0.1
Beginning Balance at Dec. 31, 2022	(74.1)	0	1.4	0.1	158.1	(233.9)	0.2
Net income (loss)	28.1
Ending Balance at Sep. 30, 2023	(24)	0	1.5	0.1	180.2	(205.8)	0
Beginning Balance at Mar. 31, 2023	(44.5)	0	1.5	0.1	180.5	(226.7)	0.1
Net income (loss)	12.7	0	0	0	0	12.7	0
Shares withheld for employee taxes	(1.1)	0	0	0	(1.1)	0	0
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0.4	0	0	0	0.4	0	0
Ending Balance at Jun. 30, 2023	(32.5)	0	1.5	0.1	179.8	(214)	0.1
Net income (loss)	8.2	0	0	0	0	8.2	0
Other comprehensive income, net of tax	(0.1)	0	0	0	0	0	(0.1)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0.4	0	0	0	0.4	0	0
Ending Balance at Sep. 30, 2023	(24)	0	1.5	0.1	180.2	(205.8)	0
Beginning Balance at Dec. 31, 2023	32.3	0	1.5	0.1	180.5	(149.5)	(0.3)
Net income (loss)	(6.1)	0	0	0	0	(6.1)	0
Stock issued during period	7.5	0	0	0	7.5	0	0
Other comprehensive income, net of tax	(0.1)	0	0	0	0	0	(0.1)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0.2	0	0	0	0.2	0	0
Ending Balance at Mar. 31, 2024	33.8	0	1.5	0.1	188.2	(155.6)	(0.4)
Beginning Balance at Dec. 31, 2023	32.3	0	1.5	0.1	180.5	(149.5)	(0.3)
Net income (loss)	19.5
Shares withheld for employee taxes					(0.1)
Ending Balance at Sep. 30, 2024	76.4	0	1.6	0.1	205.2	(130)	(0.5)
Beginning Balance at Mar. 31, 2024	33.8	0	1.5	0.1	188.2	(155.6)	(0.4)
Net income (loss)	30.6	0	0	0	0	30.6	0
Stock issued during period	12.1	0	0.1	0	12	0	0
Shares withheld for employee taxes	(0.4)	0	0	0	(0.4)	0	0
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0.5	0	0	0	0.5	0	0
Ending Balance at Jun. 30, 2024	76.6	0	1.6	0.1	200.3	(125)	(0.4)
Net income (loss)	(5)	0	0	0	0	(5)	0
Stock issued during period	4.5	0	0	0	4.5	0	0
Other comprehensive income, net of tax	(0.1)	0	0	0	0	0	(0.1)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0.4	0	0	0	0.4	0	0
Ending Balance at Sep. 30, 2024	$ 76.4	$ 0	$ 1.6	$ 0.1	$ 205.2	$ (130)	$ (0.5)

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION Basis of Presentation and Principles of Consolidation The unaudited Consolidated Financial Statements of Centrus (the “Company”), which include the accounts of the Company, its principal subsidiary, Enrichment Corp., and its other subsidiaries, as of September 30, 2024, and for the three and nine months ended September 30, 2024, and 2023, have been prepared pursuant to the rules and regulations of the SEC. The unaudited Consolidated Balance Sheet as of December 31, 2023, was derived from audited Consolidated Financial Statements, but does not include all disclosures required by U.S. GAAP. In the opinion of management, the unaudited Consolidated Financial Statements reflect all adjustments, including normal recurring adjustments, necessary for a fair statement of the financial results for the interim period. Certain prior year amounts have been reclassified for consistency with the current year presentation. Certain information and notes normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. All material intercompany transactions have been eliminated. The Company’s components of comprehensive income for the three and nine months ended September 30, 2024 and 2023, are insignificant. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The unaudited Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2023. Significant Accounting Policies The accounting policies of the Company are set forth in Note 1, Summary of Significant Accounting Policies , of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. There has not been a material change to the Company’s accounting policies since that report.

Revenue and Contracts with Cust

Revenue and Contracts with Customers	9 Months Ended
Revenue and Contracts with Customers	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	REVENUE AND CONTRACTS WITH CUSTOMERS Disaggregation of Revenue The following table presents revenue from SWU and uranium sales disaggregated by geographical region based on the billing addresses of customers (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 United States $ — $ 16.9 $ 86.1 $ 148.4 Foreign 34.8 23.6 141.9 38.5 Revenue - SWU and uranium $ 34.8 $ 40.5 $ 228.0 $ 186.9 Refer to Note 13 , Segment Information, for disaggregation of revenue by segment. Revenue for the LEU segment is derived from the sales of the SWU component of LEU, from sales of both the SWU and uranium components, and from sales of UF 6 and U 3 O 8 , to electric utility customers and other nuclear fuel related companies. Technical Solutions’ revenue is derived from services provided to the U.S. government and its contractors. SWU and uranium revenue is recognized when the customer obtains control of the SWU or uranium components and Technical Solutions’ revenue is generally recognized over time based on direct costs incurred or the right to invoice method (in situations where the value transferred matches the Company’s billing rights) as the customer receives and consumes the benefits. Accounts Receivable September 30, 2024 December 31, 2023 (in millions) Accounts receivable: Billed $ 10.2 $ 40.2 Unbilled * 8.9 9.2 Accounts receivable $ 19.1 $ 49.4 * Billings under certain contracts in the Technical Solutions segment are invoiced based on approved provisional billing rates. Unbilled revenue represents the difference between actual costs incurred and invoiced amounts. The Company expects to invoice and collect the unbilled amounts after actual rates are submitted to the customer and approved. Unbilled revenue also includes unconditional rights to payment that are not yet billable under applicable contracts due to timing of invoice processing or pending the compilation of supporting documentation. Contract Liabilities The following table presents changes in contract liability balances (in millions): September 30, December 31, Year-To-Date Change Deferred revenue - current $ 189.8 $ 252.4 $ (62.6) Advances from customers - current $ 32.8 $ 30.2 $ 2.6 Advances from customers - noncurrent $ — $ 32.8 $ (32.8) Previously deferred sales and advances from customers recognized in revenue totaled $99.6 million and $23.6 million in the nine months ended September 30, 2024 and 2023, respectively. LEU Segment The SWU component of LEU typically is sold under contracts with deliveries over several years. The Company’s agreements for natural uranium hexafluoride and uranium concentrate sales generally are shorter-term, fixed-commitment contracts. Most of the Company’s customer contracts provide for fixed purchases of SWU during a given year. Depending on the terms of specific contracts, the customer may be able to increase or decrease the quantity delivered within an agreed range. Technical Solutions Segment Revenue for the Technical Solutions segment, representing the Company’s technical, manufacturing, engineering, procurement, construction, and operations services offered to public and private sector customers, is recognized over the contractual period as services are rendered. Under the 2019 HALEU Demonstration Contract, the Company constructed a cascade of 16 centrifuges to demonstrate production of HALEU for advanced reactors. The DOE agreed to reimburse the Company for 80% of its costs incurred in performing the contract. The DOE has funded the contract up to $173.0 million with a period of performance that ended November 30, 2022. The Company recorded revenue up to the funded amount of $173.0 million and received aggregate cash payments under the HALEU Demonstration Contract of $171.2 million through September 30, 2024. Closeout activities on the HALEU Demonstration Contract are ongoing. The DOE elected to move the operational portion of the HALEU Demonstration Contract to a subsequent, competitively awarded contract and, on November 10, 2022, the DOE awarded the HALEU Operation Contract to the Company, and work began on December 1, 2022. The base contract value is approximately $150 million with two phases through 2024. Phase 1 included an approximately $30 million cost-share contribution from Centrus matched by approximately $30 million from the DOE to complete construction of the cascade, begin operations and produce the initial 20 kilograms of HALEU UF 6 by no later than December 31, 2023. On October 11, 2023, the Company announced that it began enrichment operations in Piketon, Ohio. On November 7, 2023, the Company announced that it made its first delivery of HALEU to the DOE, completing Phase 1 by successfully demonstrating its HALEU production process. Phase 2 of the HALEU Operation Contract includes production of 900 kilograms per year of HALEU UF 6 , as well as continued operations and maintenance. The DOE owns the HALEU produced from the demonstration cascade and Centrus is being compensated on a cost-plus-incentive-fee basis, with an expected Phase 2 contract value of approximately $90 million, subject to Congressional appropriations. The HALEU Operation Contract also gives DOE options to pay for up to nine additional years of production from the cascade beyond the base contract; those options are at the DOE’s sole discretion and subject to the availability of Congressional appropriations. Pursuant to an amendment to the Company’s lease for the Piketon facility, the DOE assumed all D&D liabilities arising out of the HALEU Operation Contract. Under the HALEU Operation Contract, DOE is obligated to provide the 5B Cylinders necessary to collect the output of the cascade, but supply chain challenges have created difficulties for DOE in securing enough 5B Cylinders for the entire production year. Centrus’ delivery of the 900 kilograms of HALEU UF 6 , which it no longer can achieve by November 2024, was conditioned on the DOE’s ability to provide the 5B Cylinders on a timeline that allows for continuous production throughout Phase 2 of the contract. During time periods when 5B Cylinders are insufficient, the Company is able to continue operation of the cascade, but is not able to produce HALEU. The 9% target fee for Phase 2 of the contract was estimated to be $7.5 million based on the estimated costs for the contract and is subject to a contract minimum fee of $6.9 million. To support the DOE in mitigating the risk of further delays in delivery of 5B Cylinders, the Company received technical direction and a contract modification from the DOE to procure compliant 5B Cylinders and components. The contractual obligation to furnish compliant 5B Cylinders under the HALEU Operation Contract continues to rest with the DOE. In accordance with the HALEU Operation Contract, the Company has submitted several change order requests for work being performed on infrastructure, facility repairs, and 5B Cylinders. The additional work is being performed under the DOE’s technical direction or contract modifications. On September 28, 2023, the DOE modified the HALEU Operation Contract to incorporate additional scope, not subject to cost-share reimbursement, for infrastructure and facility repairs, and costs associated with 5B Cylinder refurbishment, for an estimated additional contract value of $6.2 million. The DOE is currently obligated for costs up to approximately $6.2 million for the additional scope under the HALEU Operation Contract. Costs under the HALEU Operation Contract include program costs, including direct labor and materials and associated indirect costs that are classified as Cost of Sales, and an allocation of corporate costs supporting the program that are classified as Selling, General and Administrative Expenses . When estimates of program costs to be incurred for an integrated, construction-type contract exceed estimates of total revenue to be earned, a provision for the remaining loss on the contract is recorded to Cost of Sales in the period the loss is determined. The Company’s corporate costs supporting the program are recognized as expense as incurred over the duration of the contract term. The Company recorded an accrued loss of $21.3 million related to anticipated cost-share reimbursement under the HALEU Operation Contract in Cost of Sales in December 2022. The accrued loss on the contract was adjusted over the contract term based on actual results and remaining program cost projections through December 31, 2023. The impact to Cost of Sales in the three and nine months ended September 30, 2023 was $5.4 million and $16.7 million, respectively, for previously accrued contract losses attributable to work performed in those periods. The HALEU Operation Contract is funded incrementally, and the DOE currently is obligated for costs up to approximately $118.4 million of the $126.3 million estimated transaction price for Phase 1, Phase 2, and additional scope work. The Company has received aggregate cash payments under the HALEU Operation Contract of $95.2 million through September 30, 2024. The Company does not have a contractual obligation to perform work in excess of the funding provided by the DOE. If the DOE does not commit to additional costs above the existing funding, the Company may incur material additional costs or losses in future periods that could have an adverse impact on its financial condition and liquidity. Remaining Performance Obligations The Company’s remaining performance obligations represent the aggregate amount of total contract transaction price that is unsatisfied or partially unsatisfied. Performance obligations are recognized as revenue in future periods as work is performed or deliveries of SWU and uranium are made. The Company’s total remaining performance obligations were $0.8 billion and $1.0 billion as of September 30, 2024, and December 31, 2023, respectively, and extend to 2030. The remaining performance obligations in the LEU segment primarily related to medium and long-term contracts with fixed commitments, were approximately $0.8 billion and $1.0 billion for September 30, 2024, and December 31, 2023, respectively, and extend to 2030. The remaining performance obligations represent the estimated aggregate dollar amount of revenue for future SWU and uranium deliveries and includes approximately $223 million and $315 million of Deferred Revenue and Advances from Customers at September 30, 2024, and December 31, 2023, respectively . T he remaining performance obligations are partially based on customer estimates of the timing and size of their fuel requirements and other assumptions that are subject to change. T he remaining performance obligations include estimates of selling prices, which may be subject to change. Depending on the terms of specific contracts, prices may be adjusted based on escalation using a general inflation index, published SWU price indicators prevailing at the time of delivery, and other factors, all of which are variable. T he Company uses external composite forecasts of future market prices and inflation rates in its pricing estimates. The remaining performance obligations in the Technical Solutions segment were approximately $18.0 million and $77.0 million, as of September 30, 2024, and December 31, 2023, respectively, and extend to 2026. The remaining performance obligations in Technical Solutions include both funded (services for which funding has been both authorized and appropriated by the customer) and unfunded (services for which funding has not been appropriated) amounts. The Company does not include unexercised options or potential services under indefinite-delivery, indefinite-quantity agreements in its remaining performance obligations. If any of the Company’s contracts were to be terminated, its remaining performance obligations would be reduced by the expected value of the cancelled performance obligations of such contracts.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	9 Months Ended
Cash, Cash Equivalents and Restricted Cash	Sep. 30, 2024
Cash, Cash Equivalents and Restricted Cash [Abstract]
Cash and Cash Equivalents Disclosure	CASH, CASH EQUIVALENTS AND RESTRICTED CASH The following table summarizes the Company’s cash, cash equivalents and restricted cash as presented on the Consolidated Balance Sheets to amounts on the Consolidated Statements of Cash Flows (in millions): September 30, 2024 December 31, 2023 Cash and cash equivalents $ 194.3 $ 201.2 Deposits for financial assurance - current (a) 30.0 0.2 Deposits for financial assurance - noncurrent 2.6 32.4 Total cash, cash equivalents and restricted cash $ 226.9 $ 233.8 (a) Deposits for financial assurance - current is included within Other Current Assets in the Consolidated Balance Sheets. The Company has $0.4 million and $6.8 million denominated in euros as of September 30, 2024 and December 31, 2023, respectively, and recorded less than $0.1 million in transaction losses in both the three and nine months ended September 30, 2024 and $0.6 million in transaction losses in both the three and nine months ended September 30, 2023. The following table provides additional detail regarding the Company’s deposits for financial assurance (in millions): September 30, 2024 December 31, 2023 Current Long-Term Current Long-Term Collateral for Inventory Loans $ 29.8 $ — $ — $ 29.8 Workers Compensation — 2.5 — 2.5 Other 0.2 0.1 0.2 0.1 Total deposits for financial assurance $ 30.0 $ 2.6 $ 0.2 $ 32.4 In March, May, and October 2022, the Company entered into three inventory loans that each required a cash deposit into an escrow fund (see Note 4 , Inventories).

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2024
Inventory, Net [Abstract]
Inventories	INVENTORIES Centrus holds uranium at licensed locations (e.g., fabricators) in the form of natural uranium hexafluoride and as the uranium component of LEU in transit to meet book transfer requests by customers and suppliers. Centrus also holds SWU as the SWU component of LEU at licensed locations or in transit to meet book transfer requests by customers and suppliers. Fabricators process LEU into fuel for use in nuclear reactors. Components of inventories are as follows (in millions): September 30, 2024 December 31, 2023 Current Current Inventories, Net Current Current Inventories, Net Separative work units $ 3.2 $ 0.3 $ 2.9 $ 21.9 $ — $ 21.9 Uranium 187.5 0.5 187.0 284.5 84.3 200.2 Total $ 190.7 $ 0.8 $ 189.9 $ 306.4 $ 84.3 $ 222.1 (a) This includes inventories owed to suppliers for advances of uranium. Inventories are valued at the lower of cost or net realizable value. The Company may borrow SWU or uranium from customers or suppliers, in which case the Company will record the SWU and/or uranium and the related liability for the borrowing using a projected and forecasted purchase price over the borrowing period. In March 2023, the Company borrowed UF 6 which was recorded to inventory at a value of $22.5 million, based on the estimated fair market value of the inventory on the date of borrowing. The Company performs quarterly revaluations of Long-Term Inventory Loans reflecting an updated projection of the timing and sources of inventory to be used for repayment. These revaluations were recorded to Cost of Sales

Intangible Assets

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	INTANGIBLE ASSETS Intangible assets originated from the Company’s reorganization and application of fresh start accounting as of the date the Company emerged from bankruptcy, September 30, 2014, and reflect the conditions at that time. The intangible asset related to the LEU segment backlog is amortized as the backlog, existing at emergence, is reduced, as a result of deliveries to customers. The intangible asset related to customer relationships is amortized using the straight-line method over the estimated average useful life of 15 years. Amortization expense is presented below gross profit on the Consolidated Statements of Operations and Comprehensive Income. Intangible asset balances are as follows (in millions): September 30, 2024 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Amount Gross Carrying Amount Accumulated Amortization Net Amount Backlog $ 54.6 $ 45.4 $ 9.2 $ 54.6 $ 41.6 $ 13.0 Customer relationships 68.9 45.9 23.0 68.9 42.5 26.4 Total $ 123.5 $ 91.3 $ 32.2 $ 123.5 $ 84.1 $ 39.4

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	DEBT A summary of debt is as follows (in millions): September 30, 2024 December 31, 2023 Maturity Current Long-Term Current Long-Term 8.25% Notes: Feb. 2027 Principal $ — $ 74.3 $ — $ 74.3 Interest 6.1 9.2 6.1 15.3 Total $ 6.1 $ 83.5 $ 6.1 $ 89.6 Interest on the Company’s 8.25% Notes is payable semi-annually in arrears as of February 28 and August 31 based on a 360-day year consisting of twelve 30-day months. The 8.25% Notes were issued in connection with a troubled debt restructuring; therefore, all future interest payment obligations on the 8.25% Notes are included in the carrying value of the 8.25% Notes. As a result, interest payments are reported as a reduction in the carrying value of the 8.25% Notes and not as interest expense. As of September 30, 2024, and December 31, 2023, $6.1 million of interest was recorded as current and classified as Current Debt

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value of assets and liabilities, the following hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable: • Level 1 assets include investments with quoted prices in active markets that the Company has the ability to liquidate as of the reporting date. • Level 2 assets include investments in U.S. government agency securities, corporate and municipal debt whose estimates are valued based on observable inputs, other than quoted prices. • Level 3 assets include investments with unobservable inputs, such as third-party valuations, due to little or no market activity. Financial Instruments Recorded at Fair Value (in millions): September 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 194.3 $ — $ — $ 194.3 $ 201.2 $ — $ — $ 201.2 Deferred compensation asset (a) 0.4 — — 0.4 3.3 — — 3.3 Liabilities: Deferred compensation obligation (a) $ 0.4 $ — $ — $ 0.4 $ 3.3 $ — $ — $ 3.3 (a) The deferred compensation obligation represents the balance of deferred compensation plus net investment earnings. The deferred compensation plan is funded through a rabbi trust. Trust funds are invested in mutual funds for which unit prices are quoted in active markets and are classified within Level 1 of the valuation hierarchy. There were no transfers between Level 1, 2 or 3 during the periods presented. Other Financial Instruments As of September 30, 2024, and December 31, 2023, the Consolidated Balance Sheets carrying amounts for Accounts Receivable , Accounts Payable and Accrued Liabilities (excluding the deferred compensation obligation described above), and Payables under Inventory Purchase Agreements approximate fair value because of their short-term nature. The carrying value and estimated fair value of long-term debt were as follows (in millions): September 30, 2024 December 31, 2023 Carrying Value Estimated Fair Value (a) Carrying Value Estimated Fair Value (a) 8.25% Notes $ 89.6 (b) $ 73.8 $ 95.7 (b) $ 71.7 (a) Based on bid/ask quotes as of or near the balance sheet date, which are considered Level 2 inputs. (b) The carrying value of the 8.25% Notes consists of the principal balance of $74.3 million and the sum of current and noncurrent interest payment obligations until maturity. Refer to Note 6 , Debt

Pension and Postretirement Heal

Pension and Postretirement Health and Life Benefits	9 Months Ended
Pension and Postretirement Health and Life Benefits	Sep. 30, 2024
Retirement Benefits, Description [Abstract]
Pension and Postretirement Health and Life Benefits	PENSION AND POSTRETIREMENT HEALTH AND LIFE BENEFITS The Company provides retirement benefits to certain employees and retirees under two qualified defined benefit pension plans, one postretirement health and life benefit plan and two disqualified plans. The components of net periodic benefit costs (credits) for the defined benefit pension plans were as follows (in millions): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Service costs $ 0.5 $ 0.7 $ 1.5 $ 2.2 Interest costs 0.2 6.9 7.8 20.8 Amortization of prior service costs (credits), net 0.1 — — (0.1) Remeasurement gain (0.2) (0.9) (16.8) (0.9) Expected return on plan assets (gains) (0.2) (7.7) (9.5) (23.2) Net periodic benefit costs (credits) $ 0.4 $ (1.0) $ (17.0) $ (1.2) The components of net periodic benefit costs for the postretirement health and life benefit plan were as follows (in millions): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Interest costs $ 1.2 $ 1.2 $ 3.4 $ 3.7 Amortization of prior service costs (credits), net (0.1) (0.1) (0.1) (0.1) Net periodic benefit costs $ 1.1 $ 1.1 $ 3.3 $ 3.6 The Company reports service costs for its defined benefit pension plans and its postretirement health and life benefit plans in Cost of Sales and Selling, General and Administrative Expenses . The remaining components of net periodic benefit (credits) costs are reported as Nonoperating Components of Net Periodic Benefit Loss (Income). During the third quarter of 2023, the Company determined that it was probable that lump sum payouts for 2023 would be greater than the annual service and interest cost components of the annual net periodic benefit cost for one of its defined benefit pension plans, triggering a remeasurement. The Company’s defined benefit obligations for its pension plans was $527.3 million at December 31, 2022, of which $30.6 million related to this plan. The remeasurement resulted in a decrease in the benefit obligation and a corresponding net actuarial gain of $0.9 million for the three and nine months ended September 30, 2023. On October 12, 2023, the Company entered into an agreement with an insurer (“Insurer”) for one of its defined benefit plans to purchase a group annuity contract and transferred approximately $186.5 million of its pension plan obligations to the Insurer. The purchase of the group annuity contract was funded directly by the assets of the pension plan of approximately $171.4 million. The purchase resulted in a transfer of liabilities for approximately 1,400 participants effective December 1, 2023. The Company recorded income related to the pension settlement in the fourth quarter of $28.6 million, which was included in Nonoperating Components of Net Periodic Benefit Income in its Consolidated Statements of Operations. During the second quarter of 2024, the Company determined that it was probable that lump sum payouts for 2024 would be greater than the annual service and interest cost components of the annual net periodic benefit cost for two of its defined benefit pension plans. In addition, on May 28, 2024, the Company entered into an agreement with an insurer for two of its defined benefit plans to purchase a group annuity contract and transferred approximately $234 million of its pension plan obligations to the insurer. The purchase of the group annuity contract was funded directly by assets of the pension plan of approximately $224 million. The purchase resulted in a transfer of future benefit obligations and administrative liabilities for more than 1,000 participants effective September 1, 2024. During the third quarter of 2024, the Company again determined that it was probable that lump sum payouts for 2024 would be greater than the annual service and interest cost components of the annual net periodic benefit cost for its two defined benefit pension plans. In addition, the Company transferred $15.4 million of pension plan assets and the related obligations under two participating group annuity contracts to two non-participating group annuity contracts for two of its defined benefit plans. The purchase resulted in a transfer of future benefit obligations and administrative liabilities for more than 400 participants effective October 1, 2024. These events triggered remeasurements that resulted in a decrease in the benefit obligation and corresponding net actuarial gains of $0.2 million and $16.8 million for the three and nine months ended September 30, 2024, respectively. The related income was included in Nonoperating Components of Net Periodic Benefit Loss (Income) in the Consolidated Statements of Operations.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
Net Income (Loss) Per Share	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. In calculating diluted net income (loss) per share, the number of shares is increased by the weighted average number of potential common shares related to stock compensation awards, including restricted stock, stock options, stock appreciation rights and notional stock units, and the Warrant. No dilutive effect is recognized in a period in which a net loss has occurred. The weighted average number of common and common equivalent shares used in the calculation of basic and diluted net income (loss) per share are as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Numerator (in millions): Net income (loss) $ (5.0) $ 8.2 $ 19.5 $ 28.1 Denominator (in thousands): Average common shares outstanding - basic 16,422 15,374 16,172 15,127 Potentially dilutive shares related to stock compensation awards and warrant — 252 64 288 Average common shares outstanding - diluted 16,422 15,626 16,236 15,415 Net income (loss) per share (in dollars): Basic $ (0.30) $ 0.53 $ 1.21 $ 1.86 Diluted $ (0.30) $ 0.52 $ 1.20 $ 1.82 Common stock equivalents excluded from the diluted calculation because they would have been antidilutive (in thousands) 34 — 3 1

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2024
Equity, Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	STOCKHOLDERS’ EQUITY 2023 Shelf Registration The Company filed a shelf registration statement on Form S-3 (File No. 333-272984) with the SEC on June 28, 2023, which became effective on July 10, 2023. Pursuant to this shelf registration statement, the Company may offer and sell up to $200 million in securities, in aggregate. The Company retains broad discretion over the use of the net proceeds from the sale of the securities offered. Common Stock Issuance On February 9, 2024, the Company entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc., Lake Street Capital Markets, LLC and Roth Capital Partners, LLC (collectively, the “Agents”), relating to the ATM offering of shares of the Company’s Class A Common Stock. Pursuant to this sales agreement, the Company sold an aggregate of 115,661 and 567,491 shares of its Class A Common Stock at the market price in the three and nine months ended September 30, 2024, respectively, for a total of $4.6 million and $24.5 million, respectively. After expenses and commissions paid to the Agents, the Company’s proceeds totaled $4.5 million and $23.8 million in the three and nine months ended September 30, 2024, respectively. Additionally, the Company recorded direct costs of less than $0.1 million and $0.1 million in the three and nine months ended September 30, 2024, respectively, related to the issuance. The shares of Class A Common Stock were issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-272984), which became effective on July 10, 2023, and a prospectus supplement dated February 9, 2024. Pursuant to a separate sales agreement with its Agents, the Company sold, through its ATM offering, an aggregate of 0 and 722,568 shares of its Class A Common Stock at the market price in the three and nine months ended September 30, 2023, respectively, for a total of $0 and $24.4 million, respectively. After expenses and commissions paid to the Agents, the Company’s proceeds totaled $0 and $23.4 million in the three and nine months ended September 30, 2023, respectively. Additionally, the Company recorded direct costs of $0 and $0.2 million in the three and nine months ended September 30, 2023, respectively, related to the issuance. The shares of Class A Common Stock were issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-239242), which became effective on August 5, 2020, and two prospectus supplements dated December 31, 2020 and December 5, 2022, respectively. Unless otherwise specified in any prospectus supplement, the Company has used and/or intends to use the net proceeds from the sale of its securities offered under these prospectuses for working capital and general corporate purposes including, but not limited to, capital expenditures, repayment of indebtedness, potential acquisitions and other business opportunities. Pending any specific application, the Company may initially invest funds in short-term marketable securities or apply them to the reduction of indebtedness. Rights Agreement On May 28, 2024, the Company entered into a Sixth Amendment to the Section 382 Rights Agreement (the “Rights Agreement”), which amends the Rights Agreement, dated as of April 6, 2016, by and among the Company, and Computershare Trust Company, N.A. and Computershare Inc., as rights agent, as previously amended by (i) the First Amendment to the Rights Agreement dated as of February 14, 2017, (ii) the Second Amendment to the Rights Agreement dated as of April 3, 2019, (iii) the Third Amendment to the Rights Agreement dated as of April 13, 2020, (iv) the Fourth Amendment to the Rights Agreement dated as of June 16, 2021, and (v) the Fifth Amendment to the Rights Agreement dated as of June 20, 2023. The Fifth Amendment to the Rights Agreement (i) increased the purchase price for each one one-thousandth (1/1000th) of a share of the Company’s Series A Participating Cumulative Preferred Stock, par value $1.00 per share, from $18.00 to $160.38; and (ii) extended the Final Expiration Date (as defined in the Rights Agreement) from June 30, 2023 to June 30, 2026. The Fifth Amendment was not adopted as a result of, or in response to, any effort to acquire control of the Company. The Fifth Amendment was adopted in order to preserve for the Company’s stockholders the long-term value of the Company’s NOL carry-forwards for United States federal income tax purposes and other tax benefits. The Sixth Amendment was approved by the Board on May 28, 2024, and makes clarifying changes relating to the definition of “Beneficial Owner”, “beneficially owned” and “Beneficial Ownership” contained in the Rights Agreement. Awards under Executive Incentive Plan Under the Company’s 2019 Equity Incentive Plan, participating employees are eligible to receive grants of equity awards such as notional stock units and SARs. In April 2020, under the 2019 Equity Incentive Plan, notional stock units and SARs were granted to participating executives with a vesting period ending in April 2023. In March 2022, 2023 and 2024 restricted stock units were granted to participating executives with a vesting period ending in March 2025, 2026 and 2027, respectively. The restricted stock unit awards are time based and payable in shares of the Company’s Class A Common Stock subject to achieving a threshold level of cumulative net income over the vesting period. The grant-date fair value is included in Excess of Capital Over Par Value as the value is amortized over the vesting period. The plan payouts for the 2020-2022 performance period were settled in Class A Common Stock in March and April 2023. In the first quarter of 2023, the Company withheld $1.9 million of shares that vested during the period to fund the tax withholding obligations under the terms of the stock-based compensation plan. The Class A Common Stock issued for the 2021-2023 performance period were issued in March 2024. The Company withheld $0.1 million of shares to fund the tax withholding obligations under the terms of the stock-based compensation plan.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Commitments under SWU Purchase Agreements TENEX The Russian government-owned entity TENEX is a major supplier of SWU to the Company. Under the 2011 TENEX Supply Contract, the Company purchases SWU contained in LEU received from TENEX, and the Company delivers natural uranium hexafluoride to TENEX for the LEU’s uranium component. The LEU that the Company obtains from TENEX is subject to quotas and other restrictions applicable to commercial Russian LEU. Further, the ability of the Company or TENEX to perform under the TENEX Supply Contract is vulnerable to (i) sanctions or restrictions that have been or might be imposed by Russia, the United States, or other countries as a result of the war in Ukraine, or otherwise, (ii) customers and other parties who may object to receiving or handling Russian LEU or SWU, or (iii) suppliers and service providers seeking to limit their involvement with business related to Russia. The TENEX Supply Contract originally was signed with commitments through 2022, but was modified in 2015 to give the Company the right to reschedule certain original commitments of SWU quantities into the period 2023 and beyond, in return for the purchase of additional SWU quantities in those years. The Company has exercised this right to reschedule SWU quantities in each year through December 31, 2023. As a result of exercising this right, the Company has purchase commitments that could extend to 2028. The TENEX Supply Contract provides that the Company must pay for all SWU in its minimum purchase obligation each year, even if it fails to submit orders for such SWU. In such a case, the Company would pay for the SWU, but have to take the unordered SWU in the following year. Pricing terms for SWU under the TENEX Supply Contract are based on a combination of market-related price points and other factors. This formula was subject to an adjustment at the end of 2018 that reduced the unit costs of SWU under this contract in 2019 and for the duration of the contract. Orano In 2018, the Company entered into the Orano Supply Agreement with a French company, Orano Cycle, for the long-term supply of SWU contained in LEU. The Orano Supply Agreement subsequently was assigned by Orano Cycle to its affiliate, Orano CE. Under the amended Orano Supply Agreement, the supply of SWU runs through 2030. The Orano Supply Agreement provides significant flexibility to adjust purchase volumes, subject to annual minimums and maximums in fixed amounts that vary year by year. The pricing for the SWU purchased by the Company is determined by a formula that uses a combination of market-related price points and other factors and is subject to certain floors and ceilings. Milestones Under the 2002 DOE-USEC Agreement The Company’s predecessor, USEC Inc., and DOE signed the 2002 DOE-USEC Agreement dated June 17, 2002, pursuant to which the parties made long-term commitments directed at resolving issues related to the stability and security of the domestic uranium enrichment industry. This agreement requires Centrus to develop, demonstrate and deploy advanced enrichment technology in accordance with milestones, including the deployment of a commercial American Centrifuge Plant, and provides for remedies in the event of a failure to meet a milestone under certain circumstances, including terminating the agreement, revoking Centrus’ access to DOE’s centrifuge technology that is required for the success of the Company’s ongoing work with the American Centrifuge technology, requiring Centrus to transfer certain rights in the American Centrifuge technology and facilities to DOE, and requiring Centrus to reimburse DOE for certain costs associated with the American Centrifuge technology. The agreement provides further that if a delaying event beyond the control and without the fault or negligence of Centrus occurs that could affect Centrus’ ability to meet the American Centrifuge Plant milestones under the agreement, DOE and the Company will jointly meet to discuss in good faith possible adjustments to the milestones as appropriate to accommodate the delaying event. In 2014, the 2002 DOE-USEC Agreement and other agreements between the Company and DOE were assumed by Centrus subject to an express reservation of all rights, remedies and defenses by DOE and the Company under those agreements. DOE and the Company have agreed that all rights, remedies and defenses of the parties with respect to any missed milestones and all other matters under the 2002 DOE-USEC Agreement continue to be preserved, and that the time limits for each party to respond to any missed milestones continue to be tolled. Legal Matters From time to time, the Company is involved in various pending legal proceedings, including the pending legal proceedings described below. In 1993, USEC-Government entered into a lease for the Paducah and Portsmouth GDPs with the DOE. As part of that lease, DOE and USEC-Government also entered into a memorandum of understanding (“Power MOU”) regarding power purchase agreements between DOE and the providers of power to the GDPs. Under the Power MOU, DOE and USEC-Government agreed upon the allocation of rights and liabilities under the power purchase agreements. In 1998, USEC-Government was privatized and became Enrichment Corp., now a principal subsidiary of the Company. Pursuant to legislation authorizing the privatization, the lease for the GDPs, which included the Power MOU as an Appendix, was transferred to Enrichment Corp., and Enrichment Corp. was given the right to purchase power from DOE. The Paducah GDP was shut down in 2013 and deleased by Enrichment Corp. in 2014. On August 4, 2021, DOE informally informed Enrichment Corp. that the Joppa Power Plant, which had supplied power to the Paducah GDP, was planned to undergo D&D. According to DOE, the power purchase agreement with Electric Energy Inc. requires DOE to pay for a portion of the D&D costs of the Joppa Power Plant, and DOE has asserted that a portion of DOE’s liability is the responsibility of Enrichment Corp. under the Power MOU in the amount of approximately $9.6 million. The Company is assessing DOE’s assertions including whether all or a portion of any such potential liability had been previously settled. The Company has not formed an opinion on the merits of DOE’s claim nor is it able to estimate its potential liability, if any, for such claim and no expense or liability has been accrued. On May 26, 2019, the Company, Enrichment Corp., and six other DOE contractors who have operated facilities at the Portsmouth GDP (including, in the case of the Company, the American Centrifuge Plant site located on the premises) were named as defendants in a class action complaint filed by Ursula McGlone, Jason McGlone, Julia Dunham, and K.D. and C.D., minor children by and through their parent and natural guardian Julia Dunham (collectively, the “McGlone Plaintiffs”) in the U.S. District Court in the Southern District of Ohio, Eastern Division. The complaint seeks damages for alleged off-site contamination allegedly resulting from activities on the Portsmouth GDP site. The McGlone Plaintiffs are seeking to represent a class of (i) all current or former residents within a seven-mile radius of the Portsmouth GDP site; and (ii) all students and their parents at the Zahn’s Corner Middle School from 1993-present. The complaint was amended on December 10, 2019, and on January 10, 2020 to add additional plaintiffs and new claims. On July 31, 2020, the court granted in part and denied in part the defendants’ motion to dismiss the case. The court dismissed ten of the fifteen claims and allowed the remaining claims to proceed to the next stage of the litigation process. On August 18, 2020, the McGlone Plaintiffs filed a motion for leave to file a third amended complaint and notice of dismissal of three of the individual plaintiffs. On March 18, 2021, the McGlone Plaintiffs filed a motion for leave to file a fourth amended complaint to add new plaintiffs and allegations. On March 19, 2021, the court granted the McGlone Plaintiffs’ motion for leave to amend the complaint to include Price-Anderson Act and eight other state law claims. On May 24, 2021, the Company, Enrichment Corp., and the other defendants filed their motion to dismiss the complaint. On March 31, 2022, the court granted the Company’s motion in part by dismissing claims brought on behalf of the minor children but allowed the other claims to proceed. As such, the discovery stage of litigation is continuing. On April 28, 2022, the Company, Enrichment Corp., and the other defendants filed their answer to the fourth amended complaint. The Company believes that its operations at the Portsmouth GDP site were fully in compliance with the NRC’s regulations. Further, the Company and Enrichment Corp. believe that any such liability should be indemnified under the Price-Anderson Act. The Company and Enrichment Corp. have provided notifications to DOE required to invoke indemnification under the Price-Anderson Act and other contractual provisions. On June 8, 2022, the Company, Enrichment Corp., and six other DOE contractors who operated facilities at the Portsmouth GDP were named as defendants in a complaint filed by Brad Allen Lykins, as administrator of the estate of Braden Aaron Lee Lykins in the U.S. District Court in the Southern District of Ohio, Eastern Division (the “Lykins Complaint”). In March 2021, Brayden Lykins, who was thirteen years old, passed away from leukemia. The complaint alleges that the defendants released radiation into the environment in violation of the Price-Anderson Act causing Lykins’ death and seeks monetary damages. On August 30, 2022, the Company, Enrichment Corp., and the other defendants filed their answer to the Lykins Complaint. The Company and Enrichment Corp. believe that their operations at the Portsmouth GDP site were fully in compliance with the NRC’s regulations. Further, the Company and Enrichment Corp. believe that any such liability should be indemnified by DOE under the Price-Anderson Act. The Company and Enrichment Corp. have provided notifications to DOE required to invoke indemnification under the Price-Anderson Act and other contractual provisions. On March 8, 2023, the Company, Enrichment Corp., and six other DOE contractors that operated facilities at the Portsmouth GDP were named as defendants in a complaint filed by Christian Rose in the U.S. District Court in the Southern District of Ohio, Eastern Division (the “Rose Complaint”). Christian Rose was diagnosed with cancer in June 2022. Although Mr. Rose is an adult, he attended the Zahn’s Corner Middle School, which was closed a few years ago due to contamination and is in the vicinity of the plant. The Rose Complaint alleges that the defendants released radiation into the environment in violation of the Price-Anderson Act causing death – even though the plaintiff is still alive – and seeks monetary damages in the nature of past and future medical expenses, pain and suffering and punitive damages, among others. On May 15, 2023, the Company, Enrichment Corp. and the other defendants filed their answers to the Rose Complaint. The Company and Enrichment Corp. believe that their operations at the Portsmouth GDP site were fully in compliance with the NRC’s regulations. Further, the Company and Enrichment Corp. believe that any such liability should be indemnified under the Price-Anderson Act. The Company and Enrichment Corp. have provided notifications to the DOE required to invoke indemnification under the Price-Anderson Act and other contractual provisions. On November 27, 2023, the Company, Enrichment Corp. and six other DOE contractors who operated facilities at the Portsmouth GDP were named as defendants in a complaint filed by Joshua Shaw in the U.S. District Court in the Southern District of Ohio, Eastern Division (the “Shaw Complaint”). Joshua Shaw was diagnosed with Acute Myeloid Leukemia (“AML”) in August 2008 and after going through chemotherapy continues to experience aftereffects of AML, including anxiety and fatigue. The Shaw Complaint alleges that the defendants released radiation into the environment exposing Mr. Shaw to radiation in violation of the Price-Anderson Act and causing Mr. Shaw’s AML and other injuries. Mr. Shaw seeks monetary damages in the nature of past and future medical expenses for treatment and care, pain and suffering and punitive damages, among others. On February 26, 2024, the Company, Enrichment Corp. and the other defendants filed their motion to dismiss the Shaw Complaint, which was thereafter amended on March 14, 2024. On March 28, 2024, the Company, Enrichment Corp. and the other defendants filed their motion to dismiss the amended Shaw Complaint, and, on May 31, 2024 filed their reply to support their motion to dismiss the amended Shaw Complaint. The Company and Enrichment Corp. believe that their operations at the Portsmouth GDP site were fully in compliance with the NRC’s regulations. Further, the Company and Enrichment Corp. believe that any such liability should be indemnified under the Price-Anderson Act. The Company and Enrichment Corp. have provided notifications to the DOE required to invoke indemnification under the Price-Anderson Act and other contractual provisions. Centrus is subject to various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, Centrus does not believe that the outcome of any of these legal matters, individually and in the aggregate, will have a material adverse effect on its cash flows, results of operations, or consolidated financial condition.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2024
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Segment Information	SEGMENT INFORMATION Gross profit is the Company’s measure for segment reporting. There were no intersegment sales in the periods presented. Refer to Note 2 , Revenue and Contracts with Customers, for additional details on revenue for each segment. The following table presents the Company’s segment information (in millions): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Revenue LEU segment: Separative work units $ 34.8 $ 40.5 $ 198.1 $ 147.4 Uranium — — 29.9 39.5 Total 34.8 40.5 228.0 186.9 Technical Solutions segment 22.9 10.8 62.4 29.7 Total revenue $ 57.7 $ 51.3 $ 290.4 $ 216.6 Segment Gross Profit LEU segment $ 5.2 $ 10.1 $ 38.7 $ 60.8 Technical Solutions segment 3.7 1.2 11.0 1.5 Gross profit $ 8.9 $ 11.3 $ 49.7 $ 62.3 Revenue from Major Customers (10% or More of Total Revenue) In the three months ended September 30, 2024, one customer in the LEU segment individually represented $34.8 million of revenue. In the nine months ended September 30, 2024, four customers in the LEU segment individually represented $69.3 million, $42.3 million, $35.4 million, and $30.2 million of revenue. One customer in the Technical Solutions segment individually represented $21.6 million and $60.3 million of revenue in the three and nine months ended September 30, 2024, respectively.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Centrus follows the asset and liability approach to account for deferred taxes. Deferred tax assets and liabilities are recognized for the anticipated future tax consequences of temporary differences between the balance sheet carrying amounts of assets and liabilities and their respective tax bases. A valuation allowance is provided if it is more likely than not that all, or some portion, of the deferred tax assets may not be realized. The ultimate realization of the net deferred tax assets is dependent upon generating sufficient taxable income in future years when deferred tax assets are recoverable or are expected to reverse. During the third quarter of 2023, Centrus evaluated both positive and negative evidence that was objectively verifiable to determine the amount of the federal valuation allowance that was required on Centrus’ federal deferred tax assets. Centrus had visibility on a significant portion of revenue in the LEU segment for 2023 through 2026, primarily from its long-term sales contracts. In the third quarter of 2023, Centrus released $7.7 million of the valuation allowance against federal net deferred taxes as a discrete item for the three months ended September 30, 2023. Centrus determined that the positive evidence of increased forecasted future income in the LEU segment based on existing backlog and supply contracts along with commodity market forward pricing indicators, supported the release of the federal valuation allowance. However, due to lack of objectively verifiable information in later years, it was determined that forecasted future income was not sufficient to realize all the deferred tax assets. Therefore, Centrus recorded a partial release of its federal valuation allowance. There was no release of valuation allowance in the three and nine months ended September 30, 2024. Going forward, Centrus will continue to evaluate both positive and negative evidence that would support any further changes to the remaining valuation allowances. Such evidence in its Technical Solutions segment may include signing new contracts which could have a significant impact on pre-tax income, follow on-work related to the HALEU program, or abandonment of the commercial deployment of the centrifuge technology. Such evidence in our LEU segment may include renewing SWU sales contracts with existing customers and/or signing new SWU sales or purchase contracts with significantly higher or lower margins than currently forecasted. Additional evidence in the LEU segment may include potential deferrals in the timing of deliveries requested by its customers, which would impact revenue recognition timing. The impact of these and other potential positive and negative events will be weighed and evaluated to determine if the valuation allowance should be increased or decreased in the future.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income (loss)	$ (5)	$ 30.6	$ (6.1)	$ 8.2	$ 12.7	$ 7.2	$ 19.5	$ 28.1

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Revenue and Contracts with Cu_2

Revenue and Contracts with Customers (Tables)	9 Months Ended
Revenue and Contracts with Customers (Tables)	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue from External Customers by Geographic Areas	The following table presents revenue from SWU and uranium sales disaggregated by geographical region based on the billing addresses of customers (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 United States $ — $ 16.9 $ 86.1 $ 148.4 Foreign 34.8 23.6 141.9 38.5 Revenue - SWU and uranium $ 34.8 $ 40.5 $ 228.0 $ 186.9
Contract with Customer, Asset and Liability	September 30, 2024 December 31, 2023 (in millions) Accounts receivable: Billed $ 10.2 $ 40.2 Unbilled * 8.9 9.2 Accounts receivable $ 19.1 $ 49.4 * Billings under certain contracts in the Technical Solutions segment are invoiced based on approved provisional billing rates. Unbilled revenue represents the difference between actual costs incurred and invoiced amounts. The Company expects to invoice and collect the unbilled amounts after actual rates are submitted to the customer and approved. Unbilled revenue also includes unconditional rights to payment that are not yet billable under applicable contracts due to timing of invoice processing or pending the compilation of supporting documentation. September 30, December 31, Year-To-Date Change Deferred revenue - current $ 189.8 $ 252.4 $ (62.6) Advances from customers - current $ 32.8 $ 30.2 $ 2.6 Advances from customers - noncurrent $ — $ 32.8 $ (32.8)

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	9 Months Ended
Cash, Cash Equivalents and Restricted Cash (Tables)	Sep. 30, 2024
Cash, Cash Equivalents and Restricted Cash [Abstract]
Schedule of Cash and Cash Equivalents	The following table summarizes the Company’s cash, cash equivalents and restricted cash as presented on the Consolidated Balance Sheets to amounts on the Consolidated Statements of Cash Flows (in millions): September 30, 2024 December 31, 2023 Cash and cash equivalents $ 194.3 $ 201.2 Deposits for financial assurance - current (a) 30.0 0.2 Deposits for financial assurance - noncurrent 2.6 32.4 Total cash, cash equivalents and restricted cash $ 226.9 $ 233.8
Schedule of Restricted Cash and Cash Equivalents	The following table provides additional detail regarding the Company’s deposits for financial assurance (in millions): September 30, 2024 December 31, 2023 Current Long-Term Current Long-Term Collateral for Inventory Loans $ 29.8 $ — $ — $ 29.8 Workers Compensation — 2.5 — 2.5 Other 0.2 0.1 0.2 0.1 Total deposits for financial assurance $ 30.0 $ 2.6 $ 0.2 $ 32.4

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2024
Inventory, Net [Abstract]
Schedule of Inventories	Components of inventories are as follows (in millions): September 30, 2024 December 31, 2023 Current Current Inventories, Net Current Current Inventories, Net Separative work units $ 3.2 $ 0.3 $ 2.9 $ 21.9 $ — $ 21.9 Uranium 187.5 0.5 187.0 284.5 84.3 200.2 Total $ 190.7 $ 0.8 $ 189.9 $ 306.4 $ 84.3 $ 222.1 (a)

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
Intangible Assets (Tables)	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Excess Reorganization Value [Table Text Block]	Intangible asset balances are as follows (in millions): September 30, 2024 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Amount Gross Carrying Amount Accumulated Amortization Net Amount Backlog $ 54.6 $ 45.4 $ 9.2 $ 54.6 $ 41.6 $ 13.0 Customer relationships 68.9 45.9 23.0 68.9 42.5 26.4 Total $ 123.5 $ 91.3 $ 32.2 $ 123.5 $ 84.1 $ 39.4

Debt Schedule of Debt (Tables)

Debt Schedule of Debt (Tables)	9 Months Ended
Debt Schedule of Debt (Tables)	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Debt	A summary of debt is as follows (in millions): September 30, 2024 December 31, 2023 Maturity Current Long-Term Current Long-Term 8.25% Notes: Feb. 2027 Principal $ — $ 74.3 $ — $ 74.3 Interest 6.1 9.2 6.1 15.3 Total $ 6.1 $ 83.5 $ 6.1 $ 89.6

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Instruments Recorded at Fair Value	Financial Instruments Recorded at Fair Value (in millions): September 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 194.3 $ — $ — $ 194.3 $ 201.2 $ — $ — $ 201.2 Deferred compensation asset (a) 0.4 — — 0.4 3.3 — — 3.3 Liabilities: Deferred compensation obligation (a) $ 0.4 $ — $ — $ 0.4 $ 3.3 $ — $ — $ 3.3 (a)
Fair Value Option, Disclosures	The carrying value and estimated fair value of long-term debt were as follows (in millions): September 30, 2024 December 31, 2023 Carrying Value Estimated Fair Value (a) Carrying Value Estimated Fair Value (a) 8.25% Notes $ 89.6 (b) $ 73.8 $ 95.7 (b) $ 71.7 (a) Based on bid/ask quotes as of or near the balance sheet date, which are considered Level 2 inputs. (b) The carrying value of the 8.25% Notes consists of the principal balance of $74.3 million and the sum of current and noncurrent interest payment obligations until maturity. Refer to Note 6 , Debt

Pension and Postretirement He_2

Pension and Postretirement Health and Life Benefits (Tables)	9 Months Ended
	Sep. 30, 2024
Defined Benefit Plan Disclosure [Line Items]
Schedule of Net Benefit Costs [Table Text Block]	The components of net periodic benefit costs (credits) for the defined benefit pension plans were as follows (in millions): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Service costs $ 0.5 $ 0.7 $ 1.5 $ 2.2 Interest costs 0.2 6.9 7.8 20.8 Amortization of prior service costs (credits), net 0.1 — — (0.1) Remeasurement gain (0.2) (0.9) (16.8) (0.9) Expected return on plan assets (gains) (0.2) (7.7) (9.5) (23.2) Net periodic benefit costs (credits) $ 0.4 $ (1.0) $ (17.0) $ (1.2) The components of net periodic benefit costs for the postretirement health and life benefit plan were as follows (in millions): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Interest costs $ 1.2 $ 1.2 $ 3.4 $ 3.7 Amortization of prior service costs (credits), net (0.1) (0.1) (0.1) (0.1) Net periodic benefit costs $ 1.1 $ 1.1 $ 3.3 $ 3.6

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
Net Income (Loss) Per Share (Tables)	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Net Income Per Share	The weighted average number of common and common equivalent shares used in the calculation of basic and diluted net income (loss) per share are as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Numerator (in millions): Net income (loss) $ (5.0) $ 8.2 $ 19.5 $ 28.1 Denominator (in thousands): Average common shares outstanding - basic 16,422 15,374 16,172 15,127 Potentially dilutive shares related to stock compensation awards and warrant — 252 64 288 Average common shares outstanding - diluted 16,422 15,626 16,236 15,415 Net income (loss) per share (in dollars): Basic $ (0.30) $ 0.53 $ 1.21 $ 1.86 Diluted $ (0.30) $ 0.52 $ 1.20 $ 1.82 Common stock equivalents excluded from the diluted calculation because they would have been antidilutive (in thousands) 34 — 3 1

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2024
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Segment Reporting Information	The following table presents the Company’s segment information (in millions): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Revenue LEU segment: Separative work units $ 34.8 $ 40.5 $ 198.1 $ 147.4 Uranium — — 29.9 39.5 Total 34.8 40.5 228.0 186.9 Technical Solutions segment 22.9 10.8 62.4 29.7 Total revenue $ 57.7 $ 51.3 $ 290.4 $ 216.6 Segment Gross Profit LEU segment $ 5.2 $ 10.1 $ 38.7 $ 60.8 Technical Solutions segment 3.7 1.2 11.0 1.5 Gross profit $ 8.9 $ 11.3 $ 49.7 $ 62.3

Revenue and Contracts with Cu_3

Revenue and Contracts with Customers (Revenue from External Customers by Geographic Areas) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue	$ 57.7	$ 51.3	$ 290.4	$ 216.6
Product [Member]
Revenue	34.8	40.5	228	186.9
Product [Member] \| United States
Revenue	0	16.9	86.1	148.4
Product [Member] \| Other Foreign
Revenue	$ 34.8	$ 23.6	$ 141.9	$ 38.5

Revenue and Contracts with Cu_4

Revenue and Contracts with Customers (Contract with Customer Asset and Liability) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Deferred revenue	$ 189.8	$ 252.4
Deferred revenue – change	(62.6)
Contract With Customer, Advances, Liability, Current	32.8	30.2
Advances from customers, current	2.6
Deferred Revenue, Noncurrent	0	$ 32.8
Advances from customers, noncurrent - change	$ (32.8)

Revenue and Contracts with Cu_5

Revenue and Contracts with Customers Revenue and Contracts with Customers (Schedule of Accounts Receivable) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Billed accounts receivable	$ 10.2	$ 40.2
Unbilled contract revenue	8.9	9.2
Accounts receivable, net	$ 19.1	$ 49.4

Revenue and Contracts with Cu_6

Revenue and Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended	22 Months Ended	69 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Provision for Loss on Contracts Utilized			$ 0	$ (16.7)
Deferred revenue, revenue recognized			99.6	23.6
Revenue, remaining performance obligation, amount	$ 800		800			$ 800	$ 800	$ 1,000
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	(0.1)	$ 0.6		0.6
Accrued loss					$ 21.3
Contract Minimum Fee	6.9		6.9			6.9	6.9
LEU Segment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenue, remaining performance obligation, amount	800		800			800	800	1,000
Deferred Revenue and Advances from Customers - Current and Noncurrent	223		223			223	223	315
Technical Solutions Segment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenue, remaining performance obligation, amount	$ 18		$ 18			$ 18	$ 18	$ 77
HALEU Demo Contract
Accounts, Notes, Loans and Financing Receivable [Line Items]
Government cost share, percentage	80%		80%			80%	80%
HALEU Ops Contract
Accounts, Notes, Loans and Financing Receivable [Line Items]
Cost obligated to DOE						$ 118.4
Total Amount Program Cost						126.3
Contract Value	$ 150		$ 150			150	$ 150
New Amount Program Cost						6.2
HALEU Ops Contract \| Phase 2
Accounts, Notes, Loans and Financing Receivable [Line Items]
Contract Value	90		90			90	90
Contract Estimated Value	7.5		7.5			7.5	7.5
Government [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from Customers						95.2	173
Government [Member] \| HALEU Demo Contract
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from Customers							171.2
Government [Member] \| HALEU Ops Contract
Accounts, Notes, Loans and Financing Receivable [Line Items]
Provision for Loss on Contracts Utilized		$ 5.4		$ 16.7
Maximum [Member] \| HALEU Ops Contract \| Phase 1
Accounts, Notes, Loans and Financing Receivable [Line Items]
Government cost share portion	30		30			30	30
Company cost share portion	$ 30		$ 30			$ 30	$ 30

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cash, Cash Equivalents and Restricted Cash [Abstract]
Cash and cash equivalents	$ 194.3	$ 201.2
Restricted cash included in other current assets	30	0.2
Restricted cash included in other long-term assets	2.6	32.4
Total cash, cash equivalents and restricted cash	$ 226.9	$ 233.8	$ 215.8	$ 212.4

Cash, Cash Equivalents and Re_4

Cash, Cash Equivalents and Restricted Cash (Schedule of Restricted Cash) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2023
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash included in other current assets	$ 30			$ 0.2
Cash and Cash Equivalents, Held in Foreign Currency	0.4			6.8
Restricted cash included in other long-term assets	2.6			32.4
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	(0.1)	$ 0.6	$ 0.6
Collateral for Inventory Loan [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash included in other current assets	29.8			0
Restricted cash included in other long-term assets	0			29.8
Workers compensation financial assurance [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash included in other current assets	0			0
Restricted cash included in other long-term assets	2.5			2.5
Other financial assurance [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash included in other current assets	0.2			0.2
Restricted cash included in other long-term assets	$ 0.1			$ 0.1

Inventories (Schedule of Invent

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Inventory, Net [Abstract]
Separative work units inventory	$ 3.2	$ 21.9
Uranium inventory	187.5	284.5
Inventories	190.7	306.4
Separative work units owed to customers and suppliers	0.3	0
Uranium owed to customers and suppliers	0.5	84.3
Inventories owed to customers and suppliers	0.8	84.3
Separative work units net of liability	2.9	21.9
Uranium inventory net of liability	187	200.2
Inventories, net	$ 189.9	$ 222.1

Inventories (Narrative) (Detail

Inventories (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
Inventories (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Inventory, Net [Abstract]
UF6 units borrowed in period, value	$ 22.5
Separative work units valuation change in period		$ 1.9	$ 0.6	$ 3.7	$ 3.5

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, gross	$ 123.5	$ 123.5
Accumulated intangible asset amortization	(91.3)	(84.1)
Amortizable intangible assets, net	$ 32.2	39.4
Average useful life of finite-lived intangible assets	15 years
Contract-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, gross	$ 54.6	54.6
Accumulated intangible asset amortization	(45.4)	(41.6)
Amortizable intangible assets, net	9.2	13
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, gross	68.9	68.9
Accumulated intangible asset amortization	(45.9)	(42.5)
Amortizable intangible assets, net	$ 23	$ 26.4

Schedule of Debt (Details)

Schedule of Debt (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Long-term debt	$ 83.5	$ 89.6
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, face amount	74.3	74.3
Long-term debt, interest	9.2	15.3
Long-term debt, current	6.1	6.1
Long-term debt	$ 83.5	$ 89.6

Debt (Narrative) (Details)

Debt (Narrative) (Details) - Senior Notes [Member] - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt instrument interest rate	8.25%
Long-term debt, current	$ 6.1	$ 6.1

Fair Value Measurements (Financ

Fair Value Measurements (Financial Instruments Recorded at Fair Value) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Cash and cash equivalents	$ 194.3	$ 201.2
Deferred compensation asset	0.4	3.3
Deferred compensation obligation	0.4	3.3
Fair Value, Inputs, Level 1 [Member]
Deferred compensation asset	0.4	3.3
Deferred compensation obligation	0.4	3.3
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	0	0
Deferred compensation asset	0	0
Deferred compensation obligation	0	0
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	0	0
Deferred compensation asset	0	0
Deferred compensation obligation	$ 0	$ 0

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - Senior Notes [Member] - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt, long-term and short-term, combined carrying value	$ 89.6	$ 95.7
Long-term debt, fair value	73.8	71.7
Long-term debt, face amount	$ 74.3	$ 74.3
Debt Instrument, Interest Rate, Stated Percentage	8.25%

Pension and Postretirement He_3

Pension and Postretirement Health and Life Benefits (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	May 28, 2024	Oct. 12, 2023	Dec. 31, 2022
Defined Benefit Plan, Benefit Obligation								$ 527.3
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	$ (0.2)	$ (0.9)	$ (16.8)	$ (0.9)
Portion of Defined Benefit Plan, Benefit Obligation related to Annuity		$ 30.6		$ 30.6
Income (Loss) Related To Pension Settlement					$ 28.6
Pension Plan, Defined Benefit [Member]
Defined Benefit Plan, Pension Plan Obligation Transferred						$ 234	$ 186.5
Defined Benefit Plan, Plan Assets, Amount	$ 15.4		$ 15.4			$ 224	$ 171.4

Pension and Postretirement He_4

Pension and Postretirement Health and Life Benefits (Schedule of Net Benefit Costs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	$ (0.2)	$ (0.9)	$ (16.8)	$ (0.9)
Pension Plan, Defined Benefit [Member]
Service costs	0.5	0.7	1.5	2.2
Interest costs	0.2	6.9	7.8	20.8
Amortization of prior service costs (credits), net	0.1	0	0	(0.1)
Expected return on plan assets (gains)	(0.2)	(7.7)	(9.5)	(23.2)
Net periodic benefit cost (credit)	0.4	(1)	(17)	(1.2)
Postretirement Health and Life Benefits Plans [Member]
Interest costs	1.2	1.2	3.4	3.7
Amortization of prior service costs (credits), net	(0.1)	(0.1)	(0.1)	(0.1)
Net periodic benefit cost (credit)	$ 1.1	$ 1.1	$ 3.3	$ 3.6

Net Income (Loss) Per Share (Sc

Net Income (Loss) Per Share (Schedule of Income Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net income (loss)	$ (5)	$ 30.6	$ (6.1)	$ 8.2	$ 12.7	$ 7.2	$ 19.5	$ 28.1
Average number of shares outstanding, basic	16,422			15,374			16,172	15,127
Potentially dilutive shares related to stock options	0			252			64	288
Average number of shares outstanding, diluted	16,422			15,626			16,236	15,415
Net income (loss) per common share - basic	$ (0.30)			$ 0.53			$ 1.21	$ 1.86
Net income (loss) per common share - diluted	$ (0.30)			$ 0.52			$ 1.20	$ 1.82
Antidilutive securities excluded from computation of earnings per share	34			0			3	1

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended					9 Months Ended
	Jul. 10, 2023	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 20, 2023
Class of Stock [Line Items]
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation			$ (0.4)		$ (1.1)	$ (1.9)
Stock Issued During Period, Shares, New Issues	200,000,000	115,661		0			567,491	722,568
Stock Issued During Period, Value, Gross		$ 4.6		$ 0			$ 24.5	$ 24.4
Stock Issued During Period, Value, Net		4.5		0			23.8	23.4
Direct Costs of Stock Issuance		$ 0.1		$ 0			$ 0.1	$ 0.2
Preferred Stock, Par Value Per Share		$ 1					$ 1		$ 1
Minimum [Member]
Class of Stock [Line Items]
Purchase Price Increase Per Share									18
Maximum [Member]
Class of Stock [Line Items]
Purchase Price Increase Per Share									$ 160.38
Preferred Stock [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation			0		0	0
Common Stock [Member] \| Common Class A [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation			0		0	0
Excess of Capital over Par Value [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation			$ (0.4)		$ (1.1)	$ (1.9)	$ (0.1)

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Millions	Sep. 30, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Possible Loss Not Accrued	$ 9.6

Segment Information (Segment Re

Segment Information (Segment Reporting Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Revenue	$ 57.7	$ 51.3	$ 290.4	$ 216.6
Gross Profit	8.9	11.3	49.7	62.3
Low Enriched Uranium Segment [Member]
Segment Reporting Information [Line Items]
Gross Profit	5.2	10.1	38.7	60.8
Technical Solutions Segment [Member]
Segment Reporting Information [Line Items]
Gross Profit	3.7	1.2	11	1.5
Product [Member]
Segment Reporting Information [Line Items]
Revenue	34.8	40.5	228	186.9
Separative Work Units [Member]
Segment Reporting Information [Line Items]
Revenue	34.8	40.5	198.1	147.4
Uranium [Member]
Segment Reporting Information [Line Items]
Revenue	0	0	29.9	39.5
Service [Member]
Segment Reporting Information [Line Items]
Revenue	$ 22.9	$ 10.8	$ 62.4	$ 29.7

Segment Information Schedule Of

Segment Information Schedule Of Entity Wide Revenue By Major Customers (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Customer A [Member] \| Low Enriched Uranium Segment [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 34.8	$ 14.9	$ 69.3	$ 54.1
Customer A [Member] \| Technical Solutions Segment [Member]
Revenue, Major Customer [Line Items]
Revenue	21.6	10.7	60.3	29.4
Customer B [Member] \| Low Enriched Uranium Segment [Member]
Revenue, Major Customer [Line Items]
Revenue		12.5	$ 42.3	$ 47.8
Customer C [Member] \| Low Enriched Uranium Segment [Member]
Revenue, Major Customer [Line Items]
Revenue	35.4	$ 8.7
Customer D [Member] \| Low Enriched Uranium Segment [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 30.2

Income Taxes (Details)

Income Taxes (Details) $ in Millions	3 Months Ended
Income Taxes (Details) $ in Millions	Sep. 30, 2023 USD ($)
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ 7.7